New study tests best order of kidney cancer drugs
NCT ID NCT01217931
First seen Jan 28, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study looks at six different ways to give two drugs in sequence to people with metastatic kidney cancer. Participants receive one of three drugs (everolimus, bevacizumab, or pazopanib) and may later switch to another. The goal is to see which sequence works best and is safest. About 180 adults with clear cell kidney cancer that has spread are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.